Email Alert RSS
Volume 11 Issue 3
May  2020
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Lan-lan JI, Zhuo-li ZHANG. How to Treat Systemic Lupus Erythematosus: Interpretation of 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 283-288. DOI: 10.3969/j.issn.1674-9081.20200011
Citation: Lan-lan JI, Zhuo-li ZHANG. How to Treat Systemic Lupus Erythematosus: Interpretation of 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 283-288. DOI: 10.3969/j.issn.1674-9081.20200011
shu

How to Treat Systemic Lupus Erythematosus: Interpretation of 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus

  • Department of Rheumatology and Immunology, Peking University First Hospital, Beijing 100034, China

More Information
  • Corresponding author:

    ZHANG Zhuo-li  Tel: 86-10-83572064,E-mail:zhuoli.zhang@126.com

  • Received Date: January 12, 2020
  • Issue Publish Date: May 29, 2020
    Graphical Abstract
    • Abstract
  • 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus is the second edition that EULAR has developed for the general management of systemic lupus erythematosus (SLE) since 2007. The treatment strategy, validated goals of treatment, alternative regimens of glucocorticoids, "multi-targeted" therapy in lupus nephritis, and biological therapy for SLE were updated in the recommendations, which indicated the direction for the treatment of SLE. A detailed interpretation of the updated guidelines is provided in this article, aiming to provide references for the clinical diagnosis and treatment of SLE.
    • FullText(HTML)
    • References (14)
  • [1]
    Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus[J]. Ann Rheum Dis, 2019, 78:736-745. DOI: 10.1136/annrheumdis-2019-215089
    [2]
    Rua Figueroa Í, Erausquin C. Concerns about the Opera-tional Definition of Remission in 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus[J]. Ann Rheum Dis, 2019. doi:10.1136/annrheumdis-2019-215778.[Epub ahead of print].
    [3]
    Fanouriakis A, Bertsias G, Boumpas DT. Response to:《Concerns about the Operational Definition of Remission in 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus》 by Rua-Figueroa and Erausquin[J]. Ann Rheum Dis, 2019. Doi:10.1136/annrheumdis-2019-215810.[Epub ahead of print].
    [4]
    Petri M, Magder LS. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort[J]. Arthritis Rheumatol, 2018, 70:1790-1795. DOI: 10.1002/art.40571
    [5]
    Zen M, Iaccarino L, Gatto M, et al. Lupus Low Disease Activity State Is Associated with a Decrease in Damage Progression in Caucasian Patients with SLE, but Overlaps with Remission[J]. Ann Rheum Dis, 2018, 77:104-110. DOI: 10.1136/annrheumdis-2017-211613
    [6]
    Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association(EULAR/ERA-EDTA) Recommendations for the Manage-ment of Adult and Paediatric Lupus Nephritis[J]. Ann Rheum Dis, 2012, 71:1771-1782. DOI: 10.1136/annrheumdis-2012-201940
    [7]
    Melles RB, Marmor MF. The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine Therapy[J]. JAMA Ophthalmol, 2014, 132:1453-1460. DOI: 10.1001/jamaophthalmol.2014.3459
    [8]
    Kim JW, Kim YY, Lee H, et al. Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine[J]. J Rheumatol, 2017, 44:1674-1679. DOI: 10.3899/jrheum.170158
    [9]
    Costedoat-Chalumeau N, Isenberg D, Petri M. Letter in Response to the 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus by Fanouriakis et al[J]. Ann Rheum Dis, 2019. DOI:10.1136/annrheumdis-2019-215573.[Epub ahead of print].
    [10]
    Fanouriakis A, Bertsias G, Boumpas DT. Hydroxychloro-quine Dosing in Systemic Lupus Erythematosus:Response to 《Letter in Response to the 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus by Fanouriakis et al》 by Costedoat-Chalumeau et al[J]. Ann Rheum Dis, 2019. DOI:10.1136/annrheumdis-2019-215615.[Epub ahead of print].
    [11]
    Furer V, Rondaan C, Heijstek MW, et al. 2019 Update of EULAR Recommendations for Vaccination in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases[J]. Ann Rheum Dis, 2020, 79:39-52. DOI: 10.1136/annrheumdis-2019-215882
    [12]
    吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识小组. 吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识[J]. 中华风湿病学杂志, 2019, 23:436-440. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhfsbx98201907002
    [13]
    Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS)[J]. Ann Rheum Dis, 2011, 70:760-765. DOI: 10.1136/ard.2010.136762
    [14]
    Schanberg LE, Sandborg C, Barnhart HX, et al. Use of Atorvastatin in Systemic Lupus Erythematosus in Children and Adolescents[J]. Arthritis Rheum, 2012, 64:285-296. DOI: 10.1002/art.30645
    • Related Articles

  • Related Articles

    [1]TIAN Xinping, ZHAO Jiuliang, LI Mengtao, SONG Yijun, LIU Juntao, ZENG Xiaofeng. Interpretation on the 2022 Chinese Guideline for the Management of Pregnancy and Reproduction in Patients with Systemic Lupus Erythematous[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 504-513. DOI: 10.12290/xhyxzz.2023-0119
    [2]SHEN Tian, WU Xiaochuan. Systemic Lupus Erythematosus: from Pathogenesis to New Targeted Therapies[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 234-240. DOI: 10.12290/xhyxzz.2022-0694
    [3]WANG Lin, SONG Hongmei. Interpretation on Chinese Guidelines for the Diagnosis and Treatment of Childhood-onset Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 412-420. DOI: 10.12290/xhyxzz.2022-0018
    [4]Jiang-hong DENG, Cai-feng LI. Improving the Acknowledge of Childhood-onset Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 276-282. DOI: 10.3969/j.issn.1674-9081.20200069
    [5]Yang CUI, Xiao ZHANG. Comprehensive Management of Systemic Lupus Erythematosus During Pregnancy[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 270-275. DOI: 10.3969/j.issn.1674-9081.20200026
    [6]Bei-di CHEN, Li-dan ZHAO, Xuan ZHANG. Gut Microbiota and Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 258-263. DOI: 10.3969/j.issn.1674-9081.20200056
    [7]Nian-sheng YANG. Trends in the Pharmacological Treatment for Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 247-251. DOI: 10.3969/j.issn.1674-9081.20200061
    [8]Hua-xia YANG, Feng-chun ZHANG. New Biologic Targets for Systemic Lupus Erythematosus: Hope and Challenge[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 241-246. DOI: 10.3969/j.issn.1674-9081.20200091
    [9]Cheng-mei HE, Feng-chun ZHANG. Belimumab:A New Targeted Drug for Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 130-134. DOI: 10.3969/j.issn.1674-9081.20190114
    [10]Yuan XIA, Xiang-pei LI. The Role of MicroRNA Regulation of Interferon-α in the Pathogenesis of Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 673-678. DOI: 10.3969/j.issn.1674-9081.2019.06.021

  • Cited by

    Periodical cited type(7)

    1. 陈丽珍，陈红. 他克莫司联合利妥昔单抗治疗系统性红斑狼疮的临床疗效研究. 中国现代药物应用. 2024(09): 23-27 .
    2. 应振华，张园，王小冬. 《2020中国系统性红斑狼疮诊疗指南》解读. 浙江医学. 2022(01): 1-5 .
    3. 麦地努尔·阿不力米提，朱洪涛，布力布丽，赛比努尔·图尔荪尼亚孜. 贝利尤单抗联合糖皮质激素治疗小儿系统性红斑狼疮的临床疗效. 临床合理用药杂志. 2022(24): 144-146 .
    4. 郑宇静，黄琳，刘雪梅，金鹏飞，张亚同，封宇飞. 2016—2020年我国9个城市109家医疗卫生机构系统性红斑狼疮患者药物治疗现状调查. 中国医院用药评价与分析. 2022(08): 1005-1009+1013 .
    5. 许蕾，朱芸，张昊. 贝利尤单抗治疗系统性红斑狼疮的短期临床观察. 中国医药导报. 2021(31): 96-99 .
    6. 黄昊，席梦丹，高祥福. 基于数据挖掘研究高祥福治疗系统性红斑狼疮的用药规律. 浙江中医药大学学报. 2021(12): 1325-1330 .
    7. 白文栋，许琴，赵咏梅，席文锦，晁亚妮，何江，邹红云. 长链非编码RNA XIST在系统性红斑狼疮患者外周血CD4~+T细胞表达降低并与疾病活动度负相关. 细胞与分子免疫学杂志. 2020(09): 821-825 .

    Other cited types(4)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (657) PDF downloads (490) Cited by(11)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close